The largest database of trusted experimental protocols

Autostainer link 48 platform

Manufactured by Agilent Technologies
Sourced in Denmark, Canada, United States

The Autostainer Link 48 platform is an automated immunohistochemistry (IHC) and in situ hybridization (ISH) staining system designed to provide consistent, high-quality staining for histology samples. The platform offers walk-away automation, allowing for the efficient processing of multiple samples simultaneously.

Automatically generated - may contain errors

28 protocols using autostainer link 48 platform

1

PD-L1 IHC Staining and Scoring

Check if the same lab product or an alternative is used in the 5 most similar protocols
FFPE sections (4-µm thick) were subjected to IHC using an antibody directed against the extracellular domain of human PD-L1 (clone 22C3; Dako, Glostrup, Denmark) with 1:50 dilution. The slides were stained using a Dako Autostainer Link 48 platform with an automated staining protocol validated for the PD-L1 IHC 22C3 pharmDx assay. The pathologists A. U. and T. H. used a light microscope to score the percentage of positive tumor cells in each sample.
+ Open protocol
+ Expand
2

PD-L1 Expression Evaluation in Advanced NSCLC

Check if the same lab product or an alternative is used in the 5 most similar protocols
Assessment of the expression of programmed cell death–ligand 1 (PD‐L1) in advanced non‐small cell lung cancer (NSCLC) is now routine practice. The expression of PD‐L1 on the surface of tumor cells was evaluated by immunohistochemistry (IHC) as performed at SRL (Tokyo, Japan) with the use of a PD‐L1 IHC 22C3 pharmDx kit (Agilent Technologies, Santa Clara, CA) and a Dako Autostainer Link 48 platform (Dako, Carpinteria, CA). Staining intensity for PD‐L1 and the percentage of PD‐L1–positive tumor cells were determined for each sample by pathologists of the commercial vendor. The tumor proportion score (TPS) was calculated as the percentage of viable tumor cells showing partial or complete membrane staining (≥1+) relative to all viable tumor cells present in the sample.
+ Open protocol
+ Expand
3

Tissue Microarray Analysis of ICOS Expression in Glioma

Check if the same lab product or an alternative is used in the 5 most similar protocols
A tissue microarray (TMA), including 125 glioma samples, was produced by Outdo Biotech (Product ID: HBraG125PG01, Shanghai, China). After antigen retrieval in the PT Link IHC preprocessing system (DAKO, Denmark), the TMA was incubated with an anti-ICOS antibody (Abcam, ab105227; 1:50 dilution) overnight at 4°C. Afterward, the Autostainer Link 48 platform (DAKO, Denmark) and EnVisionTM FLEX+ (K8002, DAKO, Denmark) were employed for secondary antibody binding and color development with diaminobenzidine (DAB), followed by nuclear counterstaining with hematoxylin. Finally, the TMA results were captured with Aperio XT Slide Scanner and visualized with Aperio ImageScope software. Two pathologists independently evaluated the IHC results of TMA to identify negative or positive ICOS expression on each tissue point.
+ Open protocol
+ Expand
4

Immunohistochemical Evaluation of PD-L1

Check if the same lab product or an alternative is used in the 5 most similar protocols
PD-L1 testing was performed on formalin-fixed paraffin-embedded (FFPE) samples within 1 week after surgery. IHC of PD-L1 was conducted by 22C3 assays (Agilent Technologies) using the Dako Autostainer Link 48 platform following its manufacturer’s instructions. Tumor proportion score (TPS) of PD-L1 expression were defined as the percentage of tumor cells with positive PD-L1 staining over all tumor cells. Specimens containing less than 100 measurable tumor cells were excluded. PD-L1 expression was further categorized into no expression (TPS < 1%), low expression (TPS: 1–49%), and high expression (TPS ≥ 50%). Specimen slides were reviewed by two experienced pulmonary pathologists (Y. J. and Y. L.). Any disagreements were resolved by re-review and discussion until agreements were reached.
+ Open protocol
+ Expand
5

Quantification of Tumor-Infiltrating Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tissue microarray sections were incubated with monoclonal antibodies against CD3 (clone LN10, Menarini), CD8 (clone C8/144B, Dako), CD45RO (clone UCHL1, Dako), FoxP3 (clone 236A/E7, AbCam), T-Bet (clone 4B10, SCB), CD20 (clone L26, Dako), and CD68 (clone KP1, Dako) on a Autostainer Link48 platform (Dako) using the Flex® system for signal amplification and diaminobenzidine tetrahydrochloride–chromogen (DAB) as a chromogen.
Immunoreactive cells were automatically quantified with the Spot Browser software (Excilone), as previously described.5 (link) Measurements were recorded as the number of positive cells per mm2 of tissue surface. Results were exported into an Excel file and data from triplicate cores were consolidated into a single score that was matched to the clinicopathologic data.
+ Open protocol
+ Expand
6

Immunohistochemical Staining and Scoring of CD8 and PD-L1

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immunohistochemical (IHC) staining and scoring of CD8 were the same as in our previous research.52 (link) In detail, we spliced formalin-fixed, paraffin-embedded tumor tissues into 4 mm slides for IHC staining with CD8 antibody (1:50, ZSGB Bio, catalog No: ZA-0508) using an automated Leica Bond staining system according to the manufacturer’s protocol. The PD-L1 IHC staining procedure was performed with the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test on the Dako Autostainer Link 48 platform. For scoring the IHC image, Histoscore (H-score) was calculated by multiplying the proportion of positive cells in the sample (0–100%) by the average intensity of the positive staining (1+, 2+, or 3+) to obtain a score ranging between 0 and 300 as previously described.70 (link)
+ Open protocol
+ Expand
7

Immunohistochemical PD-L1 Staining Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serial sections of biopsy samples were prepared for IHC. PD-L1 staining using the two primary antibodies was performed on the Dako AutostainerLink-48 platform, according to the manufacturer’s instructions. The concentrated antibody clone E1L3N was applied at a dilution of 1:400 using a visualization system (K8002, without LINKER). The concentrated antibody clone 22C3 was used at a dilution of 1:50 with a visualization system (K8002, with Mouse LINKER). The slides were counterstained with hematoxylin and mounted with cover slips.
+ Open protocol
+ Expand
8

PD-L1 IHC Scoring in Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serial sections of the TMAs were immunohistochemically stained for PD-L1 using the standardized 22C3 pharmDx assay on the Dako Autostainer Link 48 platform (Dako, Carpinteria, Ca) and the standardized SP263 and SP142 assays on the Ventana Benchmark Ultra platform (Ventana Medical Systems, Tucson, AZ), according to manufacturer’s instructions.
The stained slides were evaluated simultaneously and blindly by a dedicated urological pathologist with expertise in PD-L1 evaluation (EM) and by a researcher after appropriate training (MC); discrepancies between the two observers were resolved by consensus. All tissue cores have been evaluated using both CPS (combined positive score) and IC (tumor infiltrating immune cells) scoring systems: CPS is defined as the as the number of positive tumor cells, lymphocytes and macrophages, divided by the total number of viable tumor cells multiplied by 100 (at least 100 viable tumor cells), while IC is defined as the area of tumor infiltrated by PD-L1-stained immune cells divided by the total tumor area, multiplied by 100% (at least 50 viable tumor cells).
Necrotic areas and staining artifacts were excluded from scoring.
+ Open protocol
+ Expand
9

PD-L1 Expression Assessment in FFPE Tissues

Check if the same lab product or an alternative is used in the 5 most similar protocols
FFPE tissue sections were subjected to assessment of PD-L1 expression using the PDL1 IHC 22C3 pharmDx assay (Agilent Technologies). In brief, FFPE tissue sections were dried, and fixed on positively charged slides at 56 to 60°C for 1 hour. With antigen repaired, then placed the slides in the Autostainer Link 48 platform (Dako) to incubate with the anti-human PD-L1 monoclonal antibody, clone 22C3 pharmDx, then incubated with the secondary antibody, and subsequent a substrate-chromogen solution (DAB). Tumor Proportion Score (TPS), as described previously (12 (link), 13 (link)), was calculated to evaluate PD-L1 expression level.,
+ Open protocol
+ Expand
10

Immunohistochemical Staining Protocol for FFPE Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols
All the formalin‐fixed and parrffin‐embedded (FFPE) tumor tissue blocks mentioned herein were obtained according to procedures approved by the Ninth People's Hospital (Shanghai). In brief, the FFPE tissue blocks were sliced into thin section slides and placed in an oven at 60 °C for 30–60 min. IHC was performed on tumor section slides using a Dako Autostainer Link 48 platform. The section slides were further dewaxed using EZ prep for 4 min at 72 °C. The sections immersed into Cell Conditioning Solution (CC1) were heated at 95 °C for 64 min for antigen retrieval. Cooled section slides were incubated with 3–5% H2O2 for 10 min at 37 °C to block endogenous oxidase. Subsequently, slides were incubated with primary antibody in blocking buffer for 20 min at 37 °C, followed by two washes. Sections then were incubated with HRP‐linked antibody for 8 min, followed by washing and visualization with DAB for DCIS, NSCLC, COAD, and glioma tissues. In addition, AEC chromogen was employed for visualization of SKCM tissue. Finally, the sections were incubated with Hematoxylin for 10 min and sealed. An Olympus BX41 microscope was used for scanning the stained slides.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!